TNF and psoriatic arthritis: Certolizumab is a subcutaneously administered selective immunosuppressive and anti-inflammatory TNF-α-inhibitor used to treat rheumatoid and psoriatic arthritis, spondyloarthritis, and Crohn’s disease.